Literature DB >> 17873970

Erythropoietin protects the intestine against ischemia/ reperfusion injury in rats.

Ensari Guneli1, Zahide Cavdar, Huray Islekel, Sulen Sarioglu, Serhat Erbayraktar, Muge Kiray, Selman Sokmen, Osman Yilmaz, Necati Gokmen.   

Abstract

Previous studies have shown that erythropoietin (EPO) has protective effects against ischemia/reperfusion (I/R) injury in several tissues. The aim of this study was to determine whether EPO could prevent intestinal tissue injury induced by I/R. Wistar rats were subjected to intestinal ischemia (30 min) and reperfusion (60 min). A single dose of EPO (5000 U/kg) was administered intraperitoneally at two different time points: either at five minutes before the onset of ischemia or at the onset of reperfusion. At the end of the reperfusion period, jejunum was removed for examinations. Myeloperoxidase (MPO), malondialdehyde (MDA), and antioxidant defense system were assessed by biochemical analyses. Histological evaluation was performed according to the Chiu scoring method. Endothelial nitric oxide synthase (eNOS) was demonstrated by immunohistochemistry. Apoptotic cells were determined by TUNEL staining. Compared with the sham, I/R caused intestinal tissue injury (Chiu score, 3+/-0.36 vs 0.4+/-0.24, P<0.01) and was accompanied by increases in MDA levels (0.747+/-0.076 vs 0.492+/-0.033, P<0.05), MPO activity (10.51+/-1.87 vs 4.3+/-0.45, P<0.05), intensity of eNOS immunolabelling (3+/-0.4 vs 1.3+/-0.33, P<0.05), the number of TUNEL-positive cells (20.4+/-2.6 vs 4.6+/-1.2, P<0.001), and a decrease in catalase activity (16.83+/-2.6 vs 43.15+/-4.7, P<0.01). Compared with the vehicle-treated I/R, EPO improved tissue injury; decreased the intensity of eNOS immunolabelling (1.6+/-0.24 vs 3+/-0.4, P<0.05), the number of TUNEL-positive cells (9.2+/-2.7 vs 20.4+/-2.6, P<0.01), and the high histological scores (1+/-0.51 vs 3+/-0.36, P<0.01), and increased catalase activity (42.85+/-6 vs 16.83+/-2.6, P<0.01) when given before ischemia, while it was found to have decreased the levels of MDA (0.483+/-0.025 vs 0.747+/-0.076, P<0.05) and MPO activity (3.86+/-0.76 vs 10.51+/-1.87, P<0.05), intensity of eNOS immunolabelling (1.4+/-0.24 vs 3+/-0.4, P<0.01), the number of TUNEL-positive cells (9.1+/-3 vs 20.4+/-2.6, P<0.01), and the number of high histological scores (1.16+/-0.4 vs 3+/-0.36, P<0.05) when given at the onset of reperfusion. These results demonstrate that EPO protects against intestinal I/R injury in rats by reducing oxidative stress and apoptosis. We attributed this beneficial effect to the antioxidative properties of EPO.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17873970      PMCID: PMC1976860          DOI: 10.2119/2007-00032.Guneli

Source DB:  PubMed          Journal:  Mol Med        ISSN: 1076-1551            Impact factor:   6.354


  51 in total

1.  Investigation of the bicinchoninic acid protein assay: identification of the groups responsible for color formation.

Authors:  K J Wiechelman; R D Braun; J D Fitzpatrick
Journal:  Anal Biochem       Date:  1988-11-15       Impact factor: 3.365

2.  Effect of erythropoietin on membrane lipid peroxidation, superoxide dismutase, catalase, and glutathione peroxidase of rat RBC.

Authors:  M Chakraborty; J Ghosal; T Biswas; A G Datta
Journal:  Biochem Med Metab Biol       Date:  1988-08

3.  Intestinal mucosal lesion in low-flow states. I. A morphological, hemodynamic, and metabolic reappraisal.

Authors:  C J Chiu; A H McArdle; R Brown; H J Scott; F N Gurd
Journal:  Arch Surg       Date:  1970-10

4.  Antioxidant protection: a function of tracheobronchial and gastrointestinal mucus.

Authors:  C E Cross; B Halliwell; A Allen
Journal:  Lancet       Date:  1984-06-16       Impact factor: 79.321

Review 5.  Ischemia-reperfusion injury of the intestine and protective strategies against injury.

Authors:  Ismail Hameed Mallick; Wenxuan Yang; Marc C Winslet; Alexander M Seifalian
Journal:  Dig Dis Sci       Date:  2004-09       Impact factor: 3.199

Review 6.  Erythropoietin is a multifunctional tissue-protective cytokine.

Authors:  Serhat Erbayraktar; Osman Yilmaz; Necati Gökmen; Michael Brines
Journal:  Curr Hematol Rep       Date:  2003-11

7.  Erythropoietin mediates tissue protection through an erythropoietin and common beta-subunit heteroreceptor.

Authors:  Michael Brines; Giovanni Grasso; Fabio Fiordaliso; Alessandra Sfacteria; Pietro Ghezzi; Maddalena Fratelli; Roberto Latini; Qiao-Wen Xie; John Smart; Chiao-Ju Su-Rick; Eileen Pobre; Deborah Diaz; Daniel Gomez; Carla Hand; Thomas Coleman; Anthony Cerami
Journal:  Proc Natl Acad Sci U S A       Date:  2004-09-29       Impact factor: 11.205

8.  Timing of erythropoietin treatment for cardioprotection in ischemia/reperfusion.

Authors:  Erik Lipsic; Peter van der Meer; Robert H Henning; Albert J H Suurmeijer; Kristien M Boddeus; Dirk J van Veldhuisen; Wiek H van Gilst; Regien G Schoemaker
Journal:  J Cardiovasc Pharmacol       Date:  2004-10       Impact factor: 3.105

9.  Cardioprotective effects of erythropoietin in the reperfused ischemic heart: a potential role for cardiac fibroblasts.

Authors:  Cyrus J Parsa; Jihee Kim; Ryan U Riel; Laura S Pascal; Richard B Thompson; Jason A Petrofski; Akio Matsumoto; Jonathan S Stamler; Walter J Koch
Journal:  J Biol Chem       Date:  2004-03-11       Impact factor: 5.157

Review 10.  Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics.

Authors:  J F Kerr; A H Wyllie; A R Currie
Journal:  Br J Cancer       Date:  1972-08       Impact factor: 7.640

View more
  27 in total

Review 1.  Intestinal ischemia/reperfusion: microcirculatory pathology and functional consequences.

Authors:  Brigitte Vollmar; Michael D Menger
Journal:  Langenbecks Arch Surg       Date:  2010-11-19       Impact factor: 3.445

2.  Effect of intraperitoneal erythropoietin on the degree of mucosal damage of left colon flaps in rats.

Authors:  Erdal Turk; Irfan Karaca; Aytac Karkiner; Hüseyin Evciler; Ragip Ortac; Z Gunyuz Temir; Basak Ucan; Derya Yayla
Journal:  Pediatr Surg Int       Date:  2010-02-24       Impact factor: 1.827

3.  VEGFA activates erythropoietin receptor and enhances VEGFR2-mediated pathological angiogenesis.

Authors:  Zhihong Yang; Haibo Wang; Yanchao Jiang; M Elizabeth Hartnett
Journal:  Am J Pathol       Date:  2014-03-12       Impact factor: 4.307

4.  Comparison of intestinal warm ischemic injury in PACAP knockout and wild-type mice.

Authors:  Andrea Ferencz; Peter Kiss; Gyorgy Weber; Zsuzsanna Helyes; Norihito Shintani; Akemichi Baba; Dora Reglodi
Journal:  J Mol Neurosci       Date:  2010-04-13       Impact factor: 3.444

5.  Febuxostat improves the local and remote organ changes induced by intestinal ischemia/reperfusion in rats.

Authors:  Amani Nabil Shafik
Journal:  Dig Dis Sci       Date:  2012-09-26       Impact factor: 3.199

Review 6.  Antioxidant enzyme gene transfer for ischemic diseases.

Authors:  Jian Wu; James G Hecker; Nipavan Chiamvimonvat
Journal:  Adv Drug Deliv Rev       Date:  2009-02-20       Impact factor: 15.470

7.  Protective effects of caffeic acid phenethyl ester on intestinal ischemia-reperfusion injury.

Authors:  Yuksel Yildiz; Mukadder Serter; Rauf Onur Ek; Kemal Ergin; Serpil Cecen; Ece Mine Demir; Cigdem Yenisey
Journal:  Dig Dis Sci       Date:  2008-08-06       Impact factor: 3.199

8.  Protective effects of leflunomide on intestinal ischemia-reperfusion injury: leflunomide against intestinal ischemia-reperfusion.

Authors:  Yuksel Yildiz; Hayrullah Kose; Serpil Cecen; Kemal Ergin; Ece Mine Demir; Mukadder Serter
Journal:  Dig Dis Sci       Date:  2009-02-20       Impact factor: 3.199

9.  Human adrenomedullin combined with human adrenomedullin binding protein-1 is protective in gut ischemia and reperfusion injury in the rat.

Authors:  Fangming Zhang; Rongqian Wu; Mian Zhou; Steven A Blau; Ping Wang
Journal:  Regul Pept       Date:  2008-10-07

10.  Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases.

Authors:  Douglas B Kell
Journal:  BMC Med Genomics       Date:  2009-01-08       Impact factor: 3.063

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.